Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-07-19
2011-07-19
Chunduru, Suryaprabha (Department: 1637)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S320100
Reexamination Certificate
active
07982022
ABSTRACT:
A novel strategy for monitoring the location of a transgene in a mammal is disclosed. A sodium iodide symporter is genetically fused to either the N-terminus or C-terminus of the product of a transgene through a linker peptide which bears the recognition sequence of a host cell protease. Expression of the transgene confers the activity of the sodium iodide symporter (NIS) to a host cell which expresses the transgene. Subsequent administration of labeled iodine results in transport of the labeled iodine into the cell bearing the NIS, which can then be localized and measured using standard imaging techniques. The system is particularly useful for monitoring the location of therapeutic transgenes and tissue-specific distribution of the therapeutic gene product.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4500512 (1985-02-01), Barme
patent: 4985244 (1991-01-01), Makino et al.
patent: 5001692 (1991-03-01), Farla et al.
patent: 5137727 (1992-08-01), Eckenhoff
patent: 5262359 (1993-11-01), Hierholzer
patent: 5304367 (1994-04-01), Biegon
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5661032 (1997-08-01), Miller et al.
patent: 5703056 (1997-12-01), Blasberg et al.
patent: 5713858 (1998-02-01), Heruth et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5980508 (1999-11-01), Cardamone et al.
patent: 6012034 (2000-01-01), Hamparian et al.
patent: 6026316 (2000-02-01), Kucharczyk et al.
patent: 6083751 (2000-07-01), Feldhaus et al.
patent: 6095976 (2000-08-01), Nachtomy et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6391579 (2002-05-01), Carrasco et al.
patent: 6440419 (2002-08-01), Hein et al.
patent: 2003/0118553 (2003-06-01), Petrich et al.
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/12048 (1997-04-01), None
patent: WO 9845443 (1998-10-01), None
patent: WO 99/60135 (1999-11-01), None
patent: WO 00/76450 (2000-06-01), None
Bateman A, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res., vol. 60, pp. 1492-1497, 2000.
Stratagene Catalog. Gene Characterization kits. Stratage Catalog, pp. 39, 1988.
GenBank Accession No. U60282, Nature , vol. 379 (6564) , pp. 458-460, 1996.
Abai et al., “Insulin delivery with plasmid DNA,”Hum. Gene Ther., 1999, 10(16)2637-2649.
Albonico et al., “Febrile infectious childhood diseases in the history of cancer patients and matched controls,”Medical Hypotheses, 1998, 51:315-320.
Alemany et al., “Replicative adenoviruses for cancer therapy,”Nature Biotechnology,2000, 18:723-727.
Anderson, “Human gene therapy,”Nature, 1998, 392(Supp.):25-30.
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA, 1996, 93:11313-11318.
Appelos et al., “Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis,”Gut, 1998, 42;97-102.
Arbit et al., “Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2in human brain tumors,”Eur. J. Nucl. Med., 1995, 22:419-426.
Asada, “Treatment of Human Cancer with Mumps Virus,”Cancer, 1974, 34:1907-1928.
Bae et al., “Genomic Differences between the Diabetogenic and Nondiabetogenic Variants of Encephalomyocarditis Virus,”Virology, 1989, 170:282-287.
Bateman et al., “Fusogenic Membrane Glycoproteins—A Novel Class of Cytotoxic Genes with Immunostimulatory Properties,”Gene Therapy, 1999, 6(Suppl. 1):56, Abstract #24.
Bateman et al., “Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth,”Cancer Research, 2000, 60:1492-1497 (Correction published 2000, 1 page).
Bennett et al., “Fusion of Green Fluorescent Protein with the Zeocin™-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells,”BioTechniques, 1998, 24(3):478-482.
Berg et al., “Physiological functions of endosomal proteolysis,”Biochem. J., 1995, 307:313-326.
Bluming and Ziegler, “Regression of Burkitt's Lymphoma in Association with Measles Infection,”Lancet, 1971, pp. 105-106.
Bolt and Pedersent, “The Role of Subtilisin-like Proprotein Convertases for Cleavage of the Measles Virus Fusion Glycoprotein in Different Cell Types,”Virology, 1998, 252:387-398.
Cathomen et al., “Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence,”J. Virol., 1998, 72(2):1224-1234.
Cathomen et al., “A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain,”EMBO J., 1998, 17(14):3899-3908.
Chambers et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA, 1995, 92:1411-1415
Ch'ien et al., “Fatal Subacute Immunosuppressive Measles Encephalitis (SIME) in Children with Acute Lymphcytic Leukemia—Clinical, Electroencephalographic, and Computerized Tomographic Scan Features,”Clin. Electroencephalogr., 1983, 14(4):214-220.
Cleutjens, K.B.J.M. et al, “A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans,”Molecular Endocrinology, 1997, 11:1256-1265.
Cohen et al., “Complete nucleotide sequence of an attenuated hepatitis A virus: Comparison with wild-type virus,”Proc. Natl. Acad. Sci. USA, 1987, 84:2497-2501.
Crawford et al., “Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography,”Eur. J. Nucl. Med., 1997, 24:1470-1478.
Dai et al., “Cloning and characterization of the thyroid iodide transporter,”Nature, 1996, 379:458-460.
de Felipe et al., “Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy,”Gene Ther., 1999, 6:198-208.
Delassus et al., “Genetic Organization of Gibbon Ape Leukemia Virus,”Virology, 1989, 173:205-213.
de Swart et al., “Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype,”Lancet, 2000, 355:201-202.
Douglass et al., “Polyprotein Gene Expression; Generation of Diversity of Neuroendocrine Peptides,”Ann. Rev. Biochem., 1984, 53:665-715.
Duechler et al., “Evolutionary relationships within the human rhinovirus genus: Comparison of serotypes 89, 2, and 14,”Proc. Natl. Acad. Sci. USA, 1987, 84:2605-2609.
Duprex et al., “Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus,”J. Virol., 1999, 73(11):9568-9575.
Earle et al., “The Complete Nucleotide Sequence of a Bovine Enterovirus,”J. Gen. Virol., 1988, 69:253-263.
Eiselein et al., “Treatment of Transplanted Murine Tumors with an Oncolytic Virus and Cyclophosphamide,”Cancer Res., 1978, 38:3817-3822.
Evermann and Burnstein, “Immune Enhancement of the Tumorigenicity of Hamster Brain Tumor Cells Persistently Infected with Measles Virus,”Int. J. Cancer, 1975, 16:861-869.
Flower et al., “Thyroid imaging using position emission tomography—a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis,”Br. J. Radiol., 1990, 63:325-330.
Flower et al., “Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy,”Eur. J. Nucl. Med., 1994, 21:531-536.
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth,Cancer Res., 2000, 60:1492-1497.
Galanis et al., “Use of Fusogenic Membr
Morris John
Russell Stephen J.
Chunduru Suryaprabha
Fish & Richardson P.C.
Mayo Foundation for Medical Education and Research
LandOfFree
System for monitoring the location of transgenes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System for monitoring the location of transgenes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System for monitoring the location of transgenes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668787